By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Drugs > Pilocarpine, pilocarpine hydrochloride, pilocarpine nitrate (monograph) > Pilocarpine Ophthalmic Dosage
Drugs
https://themeditary.com/dosage-information/pilocarpine-ophthalmic-dosage-10466.html

Pilocarpine Ophthalmic Dosage

Drug Detail:Pilocarpine, pilocarpine hydrochloride, pilocarpine nitrate (monograph) (Isopto carpine)

Drug Class:

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Intraocular Hypertension

Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: One drop of 1%, 2%, or 4% solution applied in the eye(s) up to four times a day

Comments:

  • Patients who are naive to this drug should be started on the 1% concentration.
  • The frequency of instillation and concentration of this drug is determined by the severity of the elevated intraocular pressure and miotic response of the patient.
  • Patients may be instructed to perform punctal occlusion for 2 minutes after instillation to limit systemic exposure to this drug.
  • This drug may be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics, or hyperosmotic agents.
  • If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

Prevention of Postoperative Elevated IOP Associated with Laser Surgery: One drop of the 1%, 2%, or 4% solution (or two drops administered five minutes apart) should be applied in the eye(s) 15 to 60 minutes prior to surgery

Comments:
  • This drug may be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics or hyperosmotic agents.
  • If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

Usual Adult Dose for Glaucoma (Open Angle)

Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: One drop of 1%, 2%, or 4% solution applied in the eye(s) up to four times a day

Comments:

  • Patients who are naive to this drug should be started on the 1% concentration.
  • The frequency of instillation and concentration of this drug is determined by the severity of the elevated intraocular pressure and miotic response of the patient.
  • Patients may be instructed to perform punctal occlusion for 2 minutes after instillation to limit systemic exposure to this drug.
  • This drug may be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics, or hyperosmotic agents.
  • If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

Prevention of Postoperative Elevated IOP Associated with Laser Surgery: One drop of the 1%, 2%, or 4% solution (or two drops administered five minutes apart) should be applied in the eye(s) 15 to 60 minutes prior to surgery

Comments:
  • This drug may be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics or hyperosmotic agents.
  • If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

Usual Adult Dose for Glaucoma (Narrow Angle)

One drop of the 1% or 2% solution applied in the eye(s) up to three times over a 30-minute period

Comments:

  • Prior to use, treatment with secretory suppressants and hyperosmotic agents may be needed to lower IOP below 50 mmHg and relieve iris ischemia.
  • If laser iridoplasty or iridomy is used to break the attack, one drop of the 4% solution should be administered prior to the procedure.
  • Following laser iridoplasty, one drop of the 1% solution should be administered four times daily until an iridotomy can be performed.
  • This drug may be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics or hyperosmotic agents.
  • If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

Use: Management of Acute Angle-Closure Glaucoma

Usual Adult Dose for Production of Miosis

One drop of 1%, 2%, or 4% solution (or two drops administered five minutes apart) should be applied in the eye(s)

Comments:

  • This drug may be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics or hyperosmotic agents.
  • If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

Use: Induction of Miosis

Usual Pediatric Dose for Glaucoma

Under 2 years:
One drop of 1% solution should be applied in the eye(s) three times a day

2 years or older:
Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: One drop of 1%, 2% or 4% solution applied in the eye(s) up to four times a day
Management of Acute Angle-Closure Glaucoma: One drop of the 1% or 2% solution applied in the eye(s) up to three times over a 30-minute period
Prevention of Postoperative Elevated IOP Associated with Laser Surgery: One drop of the 1%, 2% or 4% solution (or two drops administered five minutes apart) should be applied in the eye(s) 15 to 60 minutes prior to surgery

Comments:

  • Patients who are naive to this drug should be started on the 1% concentration.
  • The frequency of instillation and concentration of this drug is determined by the severity of the elevated intraocular pressure and miotic response of the patient.
  • This drug may be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics or hyperosmotic agents.
  • If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.
  • Prior to use, treatment with secretory suppressants and hyperosmotic agents may be needed to lower IOP below 50 mmHg and relieve iris ischemia.
  • If laser iridoplasty or iridomy is used to break the attack, one drop of the 4% solution should be administered prior to the procedure.
  • Following laser iridoplasty, one drop of the 1% solution should be administered four times daily until an iridotomy can be performed.

Uses:
  • Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
  • Management of acute angle-closure glaucoma
  • Prevention of postoperative elevated IOP associated with laser surgery
  • Induction of miosis

Usual Pediatric Dose for Intraocular Hypertension

Under 2 years:
One drop of 1% solution should be applied in the eye(s) three times a day

2 years or older:
Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: One drop of 1%, 2% or 4% solution applied in the eye(s) up to four times a day
Management of Acute Angle-Closure Glaucoma: One drop of the 1% or 2% solution applied in the eye(s) up to three times over a 30-minute period
Prevention of Postoperative Elevated IOP Associated with Laser Surgery: One drop of the 1%, 2% or 4% solution (or two drops administered five minutes apart) should be applied in the eye(s) 15 to 60 minutes prior to surgery

Comments:

  • Patients who are naive to this drug should be started on the 1% concentration.
  • The frequency of instillation and concentration of this drug is determined by the severity of the elevated intraocular pressure and miotic response of the patient.
  • This drug may be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics or hyperosmotic agents.
  • If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.
  • Prior to use, treatment with secretory suppressants and hyperosmotic agents may be needed to lower IOP below 50 mmHg and relieve iris ischemia.
  • If laser iridoplasty or iridomy is used to break the attack, one drop of the 4% solution should be administered prior to the procedure.
  • Following laser iridoplasty, one drop of the 1% solution should be administered four times daily until an iridotomy can be performed.

Uses:
  • Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
  • Management of acute angle-closure glaucoma
  • Prevention of postoperative elevated IOP associated with laser surgery
  • Induction of miosis

Usual Pediatric Dose for Production of Miosis

Under 2 years:
One drop of 1% solution should be applied in the eye(s) three times a day

2 years or older:
Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: One drop of 1%, 2% or 4% solution applied in the eye(s) up to four times a day
Management of Acute Angle-Closure Glaucoma: One drop of the 1% or 2% solution applied in the eye(s) up to three times over a 30-minute period
Prevention of Postoperative Elevated IOP Associated with Laser Surgery: One drop of the 1%, 2% or 4% solution (or two drops administered five minutes apart) should be applied in the eye(s) 15 to 60 minutes prior to surgery

Comments:

  • Patients who are naive to this drug should be started on the 1% concentration.
  • The frequency of instillation and concentration of this drug is determined by the severity of the elevated intraocular pressure and miotic response of the patient.
  • This drug may be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics or hyperosmotic agents.
  • If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.
  • Prior to use, treatment with secretory suppressants and hyperosmotic agents may be needed to lower IOP below 50 mmHg and relieve iris ischemia.
  • If laser iridoplasty or iridomy is used to break the attack, one drop of the 4% solution should be administered prior to the procedure.
  • Following laser iridoplasty, one drop of the 1% solution should be administered four times daily until an iridotomy can be performed.

Uses:
  • Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
  • Management of acute angle-closure glaucoma
  • Prevention of postoperative elevated IOP associated with laser surgery
  • Induction of miosis

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dialysis

Data not available

Other Comments

Patient advice:

  • Patients should be instructed to wash their hands before use and avoid allowing the tip of the bottle to come into contact with the eye or surrounding structures.
  • Systemic absorption of drugs from ophthalmic solutions may be minimized by
pressure on the tear-duct immediately after application.

Storage requirements:
  • Do not freeze
  • Protect from light
  • Pilocarpine nitrate: Store between 2 C to 8 C ( 36 F to 46 F)
Share this Article
Latest News
Medical News

Obesity, unhealthy lifestyles may cause heart to age by 5–45 years

May 08, 2025
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Heart disease: Just 3 minutes of 'incidental activity' may lower...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by